{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:50:39Z","timestamp":1786989039689,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,5]],"date-time":"2016-01-05T00:00:00Z","timestamp":1451952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.eururo.2015.12.050","type":"journal-article","created":{"date-parts":[[2016,1,16]],"date-time":"2016-01-16T11:08:31Z","timestamp":1452942511000},"page":"35-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer"],"prefix":"10.1016","volume":"70","author":[{"given":"Kazuhiro","family":"Yoshimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Nozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Egawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyogo","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2015.12.050_bib0145","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2015.12.050_bib0150","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2015.12.050_bib0155","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"De Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2015.12.050_bib0160","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2015.12.050_bib0165","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-na\u00efve men with metastatic castration-resistant prostate cancer (CUA-AA-302): final overall survival analysis of a randomized, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2015.12.050_bib0170","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2015.12.050_bib0175","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/pros.21261","article-title":"A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer","volume":"71","author":"Noguchi","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2015.12.050_bib0180","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1349-7006.2009.01459.x","article-title":"Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer","volume":"101","author":"Uemura","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1016\/j.eururo.2015.12.050_bib0185","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00262-010-0822-4","article-title":"A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer","volume":"59","author":"Noguchi","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.eururo.2015.12.050_bib0190","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1002\/pros.20847","article-title":"Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients","volume":"68","author":"Naito","year":"2008","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2015.12.050_bib0195","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/1097-0142(20001215)89:12<2570::AID-CNCR9>3.0.CO;2-H","article-title":"A low dose of oral dexamethasone for hormone-refractory prostate carcinoma","volume":"89","author":"Nishimura","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2015.12.050_bib0200","first-page":"252","article-title":"Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma","volume":"52","author":"Storlie","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2015.12.050_bib0205","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/1078-0432.CCR-05-2085","article-title":"Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells","volume":"12","author":"Yano","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2015.12.050_bib0210","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/jnci\/93.22.1739","article-title":"Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer","volume":"93","author":"Nishimura","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2015.12.050_bib0215","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1200\/JCO.1999.17.11.3461","article-title":"Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group","volume":"17","author":"Bubley","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.12.050_bib0220","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/pros.10276","article-title":"Cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone refractory prostate cancer patients by peptide vaccination","volume":"57","author":"Noguchi","year":"2003","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2015.12.050_bib0225","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1349-7006.2004.tb03174.x","article-title":"Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer","volume":"95","author":"Noguchi","year":"2004","journal-title":"Cancer Sci"},{"key":"10.1016\/j.eururo.2015.12.050_bib0230","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/pros.20011","article-title":"Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer","volume":"60","author":"Noguchi","year":"2004","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2015.12.050_bib0235","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer","volume":"24","author":"Small","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.12.050_bib0240","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer","volume":"28","author":"Kantoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.12.050_bib0245","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2326-6066.CIR-13-0108","article-title":"Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer","volume":"2","author":"Gulley","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.eururo.2015.12.050_bib0250","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1200\/JCO.2008.19.9968","article-title":"Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer","volume":"27","author":"McNeel","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.eururo.2015.12.050_bib0255","article-title":"Final analysis of a phase I\/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA [abstract 4535]","volume":"29","author":"K\u00fcbler","year":"2011","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.eururo.2015.12.050_bib0260","article-title":"Phase I\/II clinical trials of dendritic cell-based immunotherapy in patients with the biochemical relapse of the prostate cancer [abstract 16002]","volume":"31","author":"Spisek","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.12.050_bib0265","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.eururo.2014.10.004","article-title":"A randomized phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer","volume":"67","author":"Venkitaraman","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.12.050_bib0270","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.2013.52.3696","article-title":"Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer","volume":"32","author":"Halabi","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.12.050_bib0275","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/jnci\/djq310","article-title":"Improved endpoints for cancer immunotherapy trials","volume":"102","author":"Hoos","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2015.12.050_bib0280","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1186\/1471-2407-13-613","article-title":"A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time","volume":"13","author":"Noguchi","year":"2013","journal-title":"BMC Cancer"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816000087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816000087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T00:51:05Z","timestamp":1537059065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283816000087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0302283816000087"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2015.12.050","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2015.12.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association of Urology. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}